Clinical Trial

Detecting Beta-amyloid in the Retina

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
This study has been transferred to the Human Research Ethics Committee of St Vincent's Hospital Melbourne.
Summary
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides detailed information about retinal structure. Previous research has demonstrated a potential role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. This study aims to further evaluate the use of hyperspectral retinal imaging in the assessment of individuals with dementia or those at risk of Alzheimer's disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-08.
Trial Details
NCT Number NCT07529912
Lead Sponsor Center for Eye Research Australia
Conditions Dementia, Alzheimer Disease
Enrollment 186 participants
Start Date 2016-02-04
Primary Completion 2024-01-09 (estimated)
Study Completion 2024-01-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-24